On May 1-6, 2025, project participant Mladen Marinkovic attended the annual congress of the European Society for Radiotherapy and Oncology (ESTRO), held in Vienna, Austria, under the theme “Transformative Innovation Through Partnership.”
During the congress, Dr Marinkovic presented the results of his research work in the form of digital posters:
“Prognostic factors for disease-free interval in patients with rectal cancer treated with neoadjuvant chemoradiotherapy and dose intensification”, presented within the lower gastrointestinal cancers session
“Prognostic factors for disease-free interval in patients with rectal cancer treated with neoadjuvant chemoradiotherapy and dose intensification”, presented within the lower gastrointestinal cancers session
and
“Meta-analysis of publicly available transcriptomics data reveals predictive biomarkers for neoadjuvant chemoradiotherapy in rectal cancer”, presented in the radiobiology session.
Participation in this congress provided insight into the latest research and innovations in the field of radiation oncology, including advanced approaches to treatment planning and delivery, radiobiological foundations of personalized therapy, and the integration of artificial intelligence into clinical practice.
Moreover, the event served as a valuable platform for networking with colleagues from leading European centers, contributing significantly to the professional development and continuous improvement of both clinical and research work. The exchange of experiences and exposure to diverse methodologies and technologies are expected to enhance therapeutic strategies at the home institution.
Moreover, the event served as a valuable platform for networking with colleagues from leading European centers, contributing significantly to the professional development and continuous improvement of both clinical and research work. The exchange of experiences and exposure to diverse methodologies and technologies are expected to enhance therapeutic strategies at the home institution.
